| 摘要 |
FIELD: medicine.SUBSTANCE: tumour is sized up on the basis of which intracutaneous injections around an involved tissue prior to or after oncotomy are administered at 2-3 mm from its edge, or directly into a tumour tissue by introducing uniformly a medicinal product presented by 1.0-2.5 ml of a protein-polypeptide complex solution in a pharmaceutically acceptable carrier with the complex content (concentration) of 0.05-0.4 mg, by means of a reverse syringe needle 1-3 times a week, in the form of 6-20 injections within the therapeutic course of 4-14 procedures. The active substance is a protein-polypeptide complex produced of hoofed farm animal's nerve and skin embryonic tissue homogenate and containing negatively charged weak-acid and neutral proteins and polypeptides with molecular weight from 5 to 200 kDa and containing an average molecular weight fraction within 10 to 120 kDa of not less than 80%, with the total protein concentration of 0.2-4.2 mg/ml, the ultraviolet spectrum absorption peak of the solution at wave length 280±5 nm, the UV-visible spectrum peak at wave length 274-284 nm, the presence of specific bands in the range of pl from 4.2 to 8.4 in isoelectric focusing in 5% polyacrylamide gel. What is also presented is a method of treating the patients suffering skin cancer, such as melanoma, basal cell carcinoma, squamous cell carcinoma, wherein the above protein-peptide complex is used in the form of external applications.EFFECT: treating the above skin diseases.10 cl, 2 dwg, 6 ex |
